The DOI matches its Crossref record; 51 of the 54 references it cites were found in a registry or an index.
Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Published version of a preprint
Abstract
Purpose: NKG2D ligands (NKG2DL) are expressed on various tumor types and immunosuppressive cells within tumor microenvironments, providing suitable targets for cancer therapy. Various immune cells express NKG2D receptors, including natural killer (NK) cells and CD8+ T cells. Interactions between NKG2DL and NKG2D receptors are essential for NK-cell elimination of osteosarcoma tumor-initiating cells. In this report, we used NKG2D–NKG2DL interactions to optimize an immunotherapeutic strategy against osteosarcoma. We evaluated in vitro and in vivo the safety and cytotoxic capacity against osteosarcoma cells of CD45RA− memory T cells expressing an NKG2D-4-1BB-CD3z chimeric antigen receptor (CAR). Experimental Design: CD45RA− cells from healthy donors were transduced with NKG2D CARs containing 4-1BB and CD3z signaling domains. NKG2D CAR expression was analyzed by flow cytometry. In vitro cytotoxicity of NKG2D-CAR+ CD45RA− T cells against osteosarcoma was evaluated by performing conventional 4-hour europium-TDA release assays. For the in vivo orthotopic model, 531MII YFP-luc osteosarcoma cells were used as targets in NOD-scid IL2Rgnull mice. Results: Lentiviral transduction of NKG2D-4-1BB-CD3z markedly increased NKG2D surface expression in CD45RA− cells. Genetic stability was preserved in transduced cells. In vitro, NKG2D-CAR+ memory T cells showed significantly increased cytolytic activity than untransduced cells against osteosarcoma cell lines, while preserving the integrity of healthy cells. NKG2D-CAR+ memory T cells had considerable antitumor activity in a mouse model of osteosarcoma, whereas untransduced T cells were ineffective. Conclusions: Our results demonstrate NKG2D-4-1BB-CD3z CAR–redirected memory T cells target NKG2DL-expressing osteosarcoma cells in vivo and in vitro and could be a promising immunotherapeutic approach for patients with osteosarcoma. Clin Cancer Res; 23(19); 5824–35. ©2017 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CD45RA+memory T cells expressing an NKG2D CAR effectively killed the osteosarcoma cells in vitro and inhibited the tumor growth in mouse models of metastatic osteosarcoma with no toxicity to healthy tissues [130].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [130]
Citations
Cites
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533 · cited 1×
“HER-2–modified T cells have been shown to target osteosarcoma TICs (42), however, HER-2 is expressed at low levels in the lung, and a patient died after infusion of HER-2–redirected CAR-T cells (43).”
BackgroundPule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Regulation of Ligands for the NKG2D Activating Receptor
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 848 · cited 1×
“In addition, different NKG2DL bind NKG2D receptor with a wide range of affinities, and may vary in how they trigger or engage NKG2D, in such a way that different outcomes occur (36).”
BackgroundImai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840 · cited 1×
“The anti–CD19-41BB-CD3z CAR designed by Imai and colleagues (28) was used as backbone to build the NKG2D CAR construct.”
MethodThe who's who of T ‐cell differentiation: Human memory T ‐cell subsets
Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M., & Lugli, E. (2013) · European Journal of Immunology · doi:10.1002/eji.201343751 · Cited by 817 · cited 2×
“CD45RA is expressed on na€ ve T cells, whereas CD45RO is expressed on memory T cells (22).”
BackgroundBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652 · cited 1×
“This observation is in accordance to a decade-long safety profile of the use of genetically modified T cells (45).”
ResultBrudno, J. N., Somerville, R. P. T., Shi, V., Rose, J. J., Halverson, D. C., Fowler, D. H., Gea-Banacloche, J. C., Pavletic, S. Z., Hickstein, D. D., Lu, T. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5929 · Cited by 605 · cited 1×
“Allogeneic T cells expressing CARs have also been infused into patients after a hematopoietic stem cell transplant (HSCT) from the same healthy donor (20, 21).”
BackgroundCruz, C. R. Y., Micklethwaite, K. P., Savoldo, B., Ramos, C. A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A. J., Ito, S., et al. (2013) · Blood · doi:10.1182/blood-2013-06-506741 · Cited by 508 · cited 1×
“Allogeneic T cells expressing CARs have also been infused into patients after a hematopoietic stem cell transplant (HSCT) from the same healthy donor (20, 21).”
BackgroundMemory CD4+ T cells do not induce graft-versus-host disease
Anderson, B. E., McNiff, J., Yan, J., Doyle, H., Mamula, M., Shlomchik, M. J., & Shlomchik, W. D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17601 · Cited by 440 · cited 7×
“In contrast, CD45RA CD45ROþ T cells exert a memory response to prior pathogens or vaccines and can mediate graft-versustumor effects without inducing GvHD (25, 26).”
BackgroundInfluential
Cited by
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Xiao, L., Cen, D., Gan, H., Sun, Y., Huang, N., Xiong, H., Jin, Q., Su, L., Liu, X., Wang, K., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.011 · Cited by 323
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“CD45RA + memory T cells expressing an NKG2D CAR effectively killed the osteosarcoma cells in vitro and inhibited the tumor growth in mouse models of metastatic osteosarcoma with no toxicity to healthy tissues [130].”
BackgroundNKG2D and its ligands in cancer
Dhar, P., & Wu, J. D. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.02.004 · Cited by 239
Advances in immune checkpoint inhibitors for bone sarcoma therapy
Thanindratarn, P., Dean, D. C., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100221 · Cited by 165
“Another work showed significantly increased cytolytic activity of NKG2D-CAR+ (chimeric antigen receptor) T-lymphocytes against osteosarcoma cell lines in vitro and in murine osteosarcoma while preserving healthy cells [69] A recent study was conducted on the effectiveness of γδ T cell based immunotherapy combined with…”
BackgroundChimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00998-9 · Cited by 171
Metadata
- Authors
- Fernández, L., Metais, J.-Y., Escudero, A., Vela, M., Valentín, J., Vallcorba, I., Leivas, A., Torres, J., Valeri, A., Patiño-García, A., Martínez, J., Leung, W., & Pérez-Martínez, A.
- Affiliations
- Hospital Universitario La Paz (ES)
- 3Haematology Department, St. Jude Children's Research Hospital, Memphis, Tennessee.
- Spanish National Cancer Research Centre (ES)
- Hospital Universitario 12 De Octubre (ES)
- 8Paediatrics Laboratory, Universidad de Navarra, Pamplona, Spain.
- 1Haematological Malignancies H12O, Clinical Research Department, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
- 9Clinical Development, Miltenyi Biotec, Cambridge, Massachusetts.
- 2Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2017-10-01
- Volume
- 23
- Issue
- 19
- Pages
- 5824-5835
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2724923558
- Cited by
- 108
- References
- 54
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 16 · 2023: 12 · 2022: 10 · 2021: 13 · 2020: 13 · 2019: 15 · 2018: 4
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- ISCIII (PI15/00973)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- osteosarcoma, NKG2D, chimeric antigen receptor, memory T cells, 4-1BB, NKG2D ligands, adoptive T cell therapy, tumor microenvironment, lentiviral transduction, tumor cytotoxicity
- MeSH terms
- Animals, Female, Flow Cytometry, Humans, Immunotherapy, Killer Cells, Natural, Receptors, Antigen, T-Cell, Osteosarcoma, T-Lymphocytes, Transduction, Genetic, Neoplastic Stem Cells, Signal Transduction, Gene Expression Regulation, Neoplastic, Lentivirus, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0075
- The paper
- Fernández, L., Metais, J.-Y., Escudero, A., Vela, M., Valentín, J., Vallcorba, I., Leivas, A., Torres, J., Valeri, A., Patiño-García, A., Martínez, J., Leung, W., & Pérez-Martínez, A. (2017). Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.